ESIMIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Esimil, and when can generic versions of Esimil launch?
Esimil is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ESIMIL is guanethidine monosulfate; hydrochlorothiazide. There is one drug master file entry for this compound. Additional details are available on the guanethidine monosulfate; hydrochlorothiazide profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ESIMIL?
- What are the global sales for ESIMIL?
- What is Average Wholesale Price for ESIMIL?
Summary for ESIMIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ESIMIL at DailyMed |
US Patents and Regulatory Information for ESIMIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ESIMIL | guanethidine monosulfate; hydrochlorothiazide | TABLET;ORAL | 013553-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
